BECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER
This article was originally published in The Gray Sheet
Executive SummaryBECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER in the U.S. at a list price of $34,975. The company began taking orders for the device following its 510(k) clearance by FDA on Sept. 19. FACSCount, which provides absolute counts of CD4, CD8 and CD3 T lymphocytes, is intended for use in monitoring the status of HIV-positive patients; BD notes that the CD4 cells are the "cellular parameter most closely associated with HIV disease progression and therapy decisions."
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.